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Although intravenous (i.v.) bisphosphonates are the standard of care for metastatic bone disease, they are less than ideal for many
patients due to infusion-related adverse events (AEs), an increased risk of renal toxicity and the inconvenience of regular hospital visits.
The use of oral bisphosphonate therapy is limited by concerns over efficacy and gastrointestinal (GI) side effects. There remains a clinical
need for an oral bisphosphonate that offers equivalent efficacy to i.v. bisphosphonates, good tolerability and dosing convenience. Oral
ibandronate, a highly potent, third-generation aminobisphosphonate, has been evaluated in phase III clinical trials of patients with bone
metastases from breast cancer. In two pooled phase III studies, patients with breast cancer and bone metastases were randomised to
receive oral ibandronate 50mg (n¼287) or placebo (n¼277) once daily for up to 96 weeks. The primary end point was the skeletal
morbidity period rate (SMPR), defined as the number of 12-week periods with new skeletal complications. Multivariate Poisson’s
regression analysis was used to assess the relative risk of skeletal-related events in each treatment group during the study period. Oral
ibandronate 50mg significantly reduced the mean SMPR compared with placebo (0.95 vs 1.18, P¼0.004). There was a significant
reduction in the mean number of events requiring radiotherapy (0.73 vs 0.98, Po0.001) and events requiring surgery (0.47 vs 0.53,
P¼0.037). Poisson’s regression analysis confirmed that oral ibandronate significantly reduced the risk of a skeletal event compared with
placebo (hazard ratio 0.62, 95% CI¼0.48, 0.79; P¼0.0001). The incidence of mild treatment-related upper GI AEs was slightly higher
in the oral ibandronate 50mg group compared with placebo, but very few serious drug-related AEs were reported. Oral ibandronate
50mg is an effective, well-tolerated and convenient treatment for the prevention of skeletal complications of metastatic bone disease.
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Intravenous (i.v.) bisphosphonates are the standard of care for
patients with metastatic bone disease, with proven efficacy in
reducing skeletal complications (Hortobagyi et al, 1998; Theriault
et al, 1999; Hillner et al, 2000; Lipton et al, 2000; Rosen et al, 2001;
Pavlakis and Stockler, 2002; Body et al, 2003c). Yet, for many
patients, i.v. bisphosphonate therapy is less than ideal. The risk of
infusion-related adverse events (AEs) and the possibility of renal
toxicity adds to the treatment burden already faced by patients
with advanced cancer. The need for frequent hospital visits and
lengthy infusion duration (2h for pamidronate) can make
treatment cumbersome and inconvenient for the patient, particu-
larly as a long-term therapy.
Bisphosphonates administered via the oral route would allow
the convenience of self-administration at home. However, oral
clodronate has been shown to be less effective than i.v.
pamidronate at reducing the risk of skeletal-related events (SREs)
(Pavlakis and Stockler, 2002), and its use can be associated
with unpleasant gastrointestinal (GI) AEs, especially
diarrhoea (Kristensen et al, 1999; Powles et al, 2002). Owing to
its relatively low potency (Green et al, 1994), high doses are
required and at least two large tablets that are difficult for some
patients to swallow have to be taken daily (Paterson et al, 1993;
Robertson et al, 1995). These factors, coupled with a recommended
1-h prefood fasting period, may affect patient adherence to
treatment.
Ibandronate, a highly potent, third-generation aminobispho-
sphonate, has been developed in both i.v. and oral formulations for
the management of metastatic bone disease. As reported elsewhere,
the i.v. formulation of ibandronate (6mg infused every 3–4 weeks)
has been shown to reduce significantly the risk of skeletal
complications, alleviate bone pain and improve quality of life in
patients with metastatic breast cancer, in the absence of renal
safety concerns (Body et al, 2003a,b; Diel et al, 2003; Tripathy et al,
2003). This paper presents the results of a pooled analysis of two
phase III clinical trials that assessed the efficacy and safety of oral
ibandronate (50mgday
 1) in the treatment of women with breast
cancer and bone metastases.
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Study population
Two randomised, parallel-group, double-blind, placebo-controlled
studies were conducted by centres across Europe and other
countries, including Australia and the United States of America.
Women with histologically confirmed breast cancer and radi-
ologically confirmed bone metastases were recruited into the
studies. Patients were required to have a WHO performance status
of 0, 1 or 2, be at least 18 years of age, and to provide written
informed consent. The exclusion criteria included previous
treatment with bisphosphonates or gallium nitrate within the last
6 months, life expectancy o60 weeks, hypercalcaemia (serum
calcium, albumin corrected, X2.7mmoll
 1), hypocalcaemia (ser-
um calcium, albumin corrected, p2.0mmoll
 1), severely impaired
renal function (serum creatinine 43.0mgdl
 1), Paget’s disease of
the bone, primary hyperparathyroidism, known liver/brain me-
tastases, receiving a high-dose chemotherapy (i.e. dose intensity
43 times standard therapy), having a medical history of aspirin-
sensitive asthma, or receiving treatment with aminoglycoside
antibiotics within 4 weeks prior to the start of study medication.
In the two studies, patients were randomised to treatment with
oral ibandronate 20mg, 50mg or placebo once daily for up to 96
weeks. Only the ibandronate 50mg data (vs placebo) are reported
in this pooled analysis, as 50mg will be the recommended dose for
clinical use. Patients were instructed to take one tablet in the
morning 1h before breakfast with a glass of water, but not with
milk, milk products or calcium tablets. To assess compliance with
therapy, patients were required to return their oral medication to
the investigator every 12 weeks for checking. Concomitant
treatments were allowed during the study, except those specified
as the exclusion criteria.
Efficacy and safety assessments
Efficacy and safety data from the two studies were pooled for
analysis, as predefined in the study protocols. Fractures, bone
pain, analgesic consumption, episodes of radiotherapy and
surgical interventions were assessed at 4-weekly clinic visits. Urine
samples were collected at weeks 4, 12, 24, 48, 72 and 96 for the
assessment of c-telopeptide (CTx), a marker of bone turnover,
using Crosslapst CTx assay. AEs were recorded continuously
throughout the study.
To allow for the possibility of nonrandom withdrawal from
study groups, postwithdrawal follow-up (PWFU) efficacy and
safety data (i.e. for the period from study withdrawal until death or
the last scheduled study visit) were also collected. Postwithdrawal
follow-up data collection were discontinued when treatment with
another bisphosphonate began.
Analysis of efficacy
The primary efficacy parameter was the skeletal morbidity period
rate (SMPR) defined as the number of 12-week periods with new
skeletal complications, divided by the total observation time.
Skeletal complications included vertebral fractures, pathological
nonvertebral fractures, radiotherapy for bone complications
(uncontrolled bone pain or impending fractures) and surgery for
bone complications (fractures or impending fractures). To allow
for the time spent in the study, SMPR was calculated using a
revised event ratio method, as follows (Scott et al, 2003):
SMPR ¼
numberof periodswithnewskeletalevents þ 1
numberof 12 weekperiodsonstudy þ 0:5
As prespecified in the data analysis plan, analyses of the primary
end point excluded data collected in the first 12-week period.
Exclusion of early events avoids the loss of power associated with
events occurring too early to have been prevented by bispho-
sphonates. It was anticipated that effects on bone events of
ibandronate vs placebo would begin to appear 6–8 weeks after
drug initiation. The first 12 weeks were selected for exclusion as
study visits were on a 3-month basis.
Supportive analyses of the SMPR included the mean number of
skeletal events per patient, the mean number of 12-week
measurement periods with events per patient, the percentage of
patients with skeletal events and time to first new bone event. A
multivariate Poisson’s regression analysis was performed to assess
the risk of developing a skeletal event over the entire 96 weeks of
treatment, while controlling for any differences in baseline
characteristics between the oral ibandronate 50mg group and
the placebo group. The input variables for the Poisson’s regression
analysis were country, age, estrogen/progesterone receptor status,
performance status, time from breast cancer and metastatic bone
disease diagnoses to study initiation, extraosseous metastases,
prior hormone and chemotherapy, pathological fractures at
baseline, pain score, analgesic score and baseline laboratory
measures (e.g. haemoglobin, alkaline phosphatase, aspartate
transaminase, white blood cell counts).
Statistics
The global null hypothesis (no difference in SMPR between
ibandronate and placebo) was tested at the two-sided a-level of 5%
using the nonparametric Jonckheere–Terpstra method (Terpstra,
1952; Jonckheere, 1954). If the global hypothesis was rejected,
pairwise comparisons between treatments were performed using
the Wilcoxon’s rank-sum method, maintaining an overall two-
sided a-level of 5% and following a closed-test procedure. The trial
was designed such that the statistical analysis of the study was
powered for the composite end point SMPR, but not for the
components of the composite. Efficacy analyses were conducted on
the intent-to-treat (ITT) population (all patients randomised) and
included PWFU data. Evaluation of safety was based on all
randomised patients who had received at least one dose of study
drug and had at least one follow-up assessment.
Ethics
The study was performed in accordance with the principles of the
Declaration of Helsinki, the Guidelines on Good Clinical Practice
and local medicines legislation in place at the time of study
initiation.
RESULTS
Patients
A total of 564 patients were randomised to treatment with oral
ibandronate 50mg (n¼287) or placebo (n¼277) and were
included in the ITT analysis. Patient demographics and baseline
characteristics are shown in Table 1. Although the study groups
were generally comparable at baseline, the oral ibandronate 50mg
group contained a higher percentage of patients receiving ongoing
cytotoxic therapy, with a higher mean bone pain score and a
higher percentage of patients with pre-existing fractures than in
the placebo group (differences between groups nonsignificant).
The percentage of patients completing the 96-week treatment
period was 42% in the ibandronate group and 38% in the placebo
group. The median time on study (from randomisation to study
end) was 79 weeks with ibandronate compared with 69 weeks with
placebo (NS). The most frequent reasons for withdrawal were
malignancy progression (affecting 12% of patients receiving
ibandronate vs 19% of patients receiving placebo), death (15 vs
12%) and other AEs (10 vs 12%).
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The mean SMPR for all new bone events was significantly reduced
with oral ibandronate 50mg compared with placebo (P¼0.004)
(Figure 1). Analysis of the individual components revealed that
this effect was due primarily to significant reductions in bone
events requiring radiotherapy (Po0.001) or surgery (P¼0.037)
(Figure 1). There was no significant difference in the number of
skeletal fractures with ibandronate compared with placebo
(P¼0.195). When bone events occurring during the first 12-week
period were included in the SMPR calculation, the impact of
ibandronate on the incidence of skeletal events was reduced, but
remained significant for overall SMPR and for events requiring
radiotherapy (Table 2). Supportive analyses of new bone events
demonstrated that the mean number of events and the mean
number of measurement periods with events per patient were
significantly reduced in the ibandronate group compared with
placebo (P¼0.008 and 0.015, respectively, Table 3). The median
time to first bone event was 90.3 weeks with oral ibandronate
50mg and 64.9 weeks with placebo (P¼0.089).
Multivariate Poisson’s regression analysis showed that the risk
reduction for a skeletal event in the ibandronate 50mg group was
significantly lower than in the placebo group (hazard ratio 0.62,
95% CI¼0.48, 0.79, Po0.0001), translating to a 38% risk
reduction for ibandronate vs placebo.
Patients receiving oral ibandronate 50mg showed a significant
decrease from baseline in the bone marker urinary CTx over the
96-week study period compared with placebo (median change
 77.3% and þ11.0%, Po0.001) (Figure 2).
Safety
A total of 563 patients were included in the safety analysis. As
would be expected with skeletal metastases due to advanced
cancer, almost all patients reported AEs during the course of the
study. The percentage of patients experiencing any AE was similar
between the oral ibandronate 50mg and placebo groups (94.4 vs
95.3%). The most frequently recorded AE was malignancy
progression (affecting 67.5 and 70.8% of patients, respectively).
There was a slightly higher incidence of drug-related AEs with
ibandronate (26.6%) than with placebo (17.7%), primarily due to
more reports of hypocalcaemia in the ibandronate group (Table 4),
a side effect associated with the use of any bisphosphonate. Serious
AEs that were considered to be drug related were experienced by
1.0% of patients receiving ibandronate, compared with 1.4% of
patients in the placebo group.
The incidence of mild treatment-related upper GI AEs (dyspepsia,
nausea and oesophagitis) was slightly higher in the oral ibandronate
50mg group compared with placebo (Table 4). The incidence of
drug-related upper GI AEs known to be associated with oral
bisphosphonate administration was similar in the placebo and
50mg oral ibandronate groups (Table 4). Only two serious upper GI
Table 1 Patient demographics and baseline characteristics
Placebo
(n¼277)
Ibandronate,
50mg (n¼287)
Age (years)
Median (range) 56 (26–87) 57 (27–92)
Race, Caucasian (%) 94 93
Median time from diagnosis to first drug
intake (years)
3.87 3.44
Median time from bone metastases
diagnosis to study entry (years)
0.48 0.46
Performance status (%)
WHO grade 0 or 1 85 84
WHO grade 2 15 16
Mean pain score 1.13 1.33
Mean analgesic score 0.98 1.09
Prior fractures at baseline (%) 43 52
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Figure 1 Summary of the mean SMPR, weighted for observation time
(*Po0.05, **Po0.01 and ***Po0.001).
Table 2 Supportive analysis of SMPR, including events occurring during
the first 12 weeks of treatment
Mean SMPR Placebo Ibandronate, 50mg
All new bone events 1.15 0.99, P¼0.041*
Vertebral fractures 0.52 0.49, P¼0.145*
Nonvertebral fractures 0.52 0.51, P¼0.330*
Need for radiotherapy 0.98 0.80, Po0.004*
Need for surgery 0.44 0.40, P¼0.098*
SMPR¼skeletal morbidity period rate. *Wilcoxon’s rank-sum test, pairwise
comparisons vs placebo.
Table 3 Supportive analyses of new bone events
Placebo
Ibandronate,
50mg
No. of events per patient 1.85 1.15, P¼0.008*
No. of 12-week periods with events per patient 0.99 0.71, P¼0.015*
% of patients with events 52.2 45.3, P¼0.122*
*Wilcoxon’s rank-sum test, pairwise comparisons vs placebo.
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Figure 2 Change in urinary CTx during study period (*Po0.001).
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patient) were considered related to ibandronate treatment.
The incidence of renal AEs was comparable between ibandro-
nate (5.2%) and placebo (4.7%), and there were no reports of
serious AEs (renal failure) in the active treatment group.
During the course of the study, 20% of patients (n¼57) in the
ibandronate 50mg group and 15% of patients (n¼42) in the
placebo group died as a result of an AE. Death was most commonly
due to malignancy progression, and no deaths were considered to
be related to study treatment.
DISCUSSION
The primary efficacy measure used in these two phase III trials of
oral ibandronate was the SMPR, defined as the number of 12-week
periods with new bone events, weighted for observation time. By
assessing 12-week time periods where all complications are
considered as a single occurrence, the SMPR avoids multiple
counting of events, and therefore represents a conservative
measure of efficacy. Clinical trials of other bisphosphonates in
patients with metastatic bone disease have used the SRE or skeletal
morbidity rate to assess the impact of treatment on skeletal
complications. By counting all occurrences of new bone events,
these measures may overestimate the effect of treatment, as many
skeletal events (e.g. radiotherapy, fracture and bone surgery) are
likely to be related in many cases.
The pooled results of the two oral trials demonstrated that
ibandronate 50mg once daily effectively reduces the incidence of
new bone events in women with breast cancer and bone
metastases. A statistically significant clinical benefit was observed
for overall SMPR compared with placebo. This effect was
maintained when skeletal events occurring in the first 12-week
treatment period (including prescheduled radiotherapy events,
which may have reduced the observed effect of active treatment)
was included in the analysis. Ibandronate also significantly
improved the need for bone radiotherapy and the need for bone
surgery, both of which are considered to be highly clinically
relevant indicators of disease outcomes. As the study was not
powered to detect statistical significance on individual components
of the SMPR, these results strongly support the clinical impact of
ibandronate on the occurrence of new bone events. The results for
fractures did not reach statistical significance in contrast to the
data for i.v. ibandronate (Body et al, 2003a), and the patients had
overall less fractures in the oral studies. Since a large meta-analysis
of clinical trials has shown that bisphosphonates significantly
decrease skeletal morbidity including fractures and need for
radiotherapy (Ross et al, 2003), the trend that was observed for
oral ibandronate will need to be confirmed in larger studies.
The percentage reduction in SMPR with oral ibandronate vs
placebo in this pooled analysis (19%) was comparable to that
observed in a clinical trial of i.v. ibandronate 6mg (20%), which
had a similar study design and was also conducted in patients with
metastatic breast cancer (Body et al, 2003a,c). The Poisson’s
regression analysis conducted on the pooled data set and the
results of the i.v. trial also revealed comparable reductions in the
risk of SREs with oral and i.v. ibandronate compared with placebo
(hazard ratio 0.62, P¼0.001 and hazard ratio 0.60, P¼0.0033,
respectively) (Body et al, 2003a,c). Comparisons between these
trials are cautious, as patients in the i.v. study had received a
diagnosis of metastatic bone disease approximately 10 months
earlier prior to study entry than patients in the oral trials,
indicating that they had more severe disease. However, patients in
the trials were similar in terms of their clinical presentation (age,
baseline fracture incidence, performance status and bone-pain
level), suggesting that the oral and i.v. formulations had broadly
similar efficacy. Supporting this, oral and i.v. ibandronate were
shown to have similar effects on secondary efficacy end points,
with bone pain significantly reduced and maintained below
baseline over 2 years of treatment, and significantly less
deterioration in quality of life compared with placebo (Body et al,
2003b; Tripathy et al, 2003). This would be expected given that a
daily oral 50mg dose and an i.v. 6mg given every 3–4 weeks
provide the same bone surface exposure to ibandronate (Leyland-
Jones, in press). Direct comparisons between bisphosphonates are
difficult because of differences in study methodology. A compara-
tive trial is currently examining the effects of oral ibandronate and
i.v. zoledronate in patients with metastatic bone disease due to
breast cancer.
Long-term drug safety and tolerability is an important
consideration in the selection of treatment for skeletal metastases,
due to the high disease-related morbidity burden and the side
effects associated with systemic cancer therapy. Oral ibandronate
50mgday
 1 for 2 years of treatment was well tolerated in these
trials, with an AE profile quite similar to placebo. As demonstrated
for i.v. ibandronate (Body et al, 2003a; Lyubimova et al, 2003), oral
ibandronate was not associated with renal AEs. This contrasts with
the enhanced risk of renal AEs reported with i.v. zoledronate and
pamidronate in a phase III trial (Rosen et al, 2001). With its benign
renal safety profile, oral ibandronate may be used in patients with
existing renal impairment. In addition, the results suggest that
serum creatinine monitoring can be made, depending on the
assessment of the individual patient, at the clinician’s discretion.
The associated reductions in renal monitoring time and costs
could help to relieve the burden of bisphosphonate care on nursing
staff and hospital budgets (Body, 2003).
As well as efficacy and safety, the availability of oral ibandronate
could offer improved treatment flexibility for physicians and
convenience for patients. Oral ibandronate may be prescribed
alongside other oral agents (particularly hormonal treatment) for at-
home dosing (e.g. when hospital care is not being received). Patients
would no longer have to spend time travelling to and from the
hospital solely for bisphosphonate infusion, allowing them to
maintain their lifestyle without unnecessary disruption. The dosing
regimen of oral ibandronate is convenient for patients. Adequate
adherence is important in real-life situations, where dosing
instructions are not closely monitored, unlike in clinical trials.
In conclusion, oral ibandronate 50mg is an effective, well-
tolerated and convenient treatment for the skeletal complications
of metastatic bone disease.
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